Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 11,176 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Alzheimer Disease
Interventions: Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet; Drug
Lead sponsor: Cassava Sciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more

Conditions: Cystic Fibrosis
Interventions: Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF), Supportive Psychotherapy (Treatment as Usual Control); Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Adult Participants
Interventions: TBD11, Placebo; Drug
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Adult Participants
Interventions: Oral [14C] PF-07248144, Oral unlabeled PF-07248144, IV [14C] PF-07248144; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Language Development
Interventions: TMW ECE Curriculum; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Postoperative Facial Ecchymosis, Postoperative Facial Edema
Interventions: ELIXIR MD Photobiomodulation (PBM) System; Device
Lead sponsor: Elixir MD Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Phenylketonurias, PAH Deficiency
Interventions: HMI-102; Genetic
Lead sponsor: Homology Medicines, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Tampa, Florida + 10 more

Conditions: Plaque Psoriasis
Interventions: ASC50 tablets or matching placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non Small Cell Lung Cancer
Interventions: Aglatimagene besadenovec; Biological
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Farmington, Connecticut • New Haven, Connecticut + 10 more

Conditions: Healthy, Drug Drug Interaction
Interventions: Itraconazole, Rifampin, KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 35 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Interventions: IM JZP-458, IV JZP-458; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Large-cell Lymphoma
Interventions: Rapcabtagene autoleucel (YTB323); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Neuronal Ceroid Lipofuscinosis CLN5
Interventions: NGN-101; Genetic
Lead sponsor: Neurogene Inc.; Industry
Eligibility: 3 Years to 9 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Select Advanced Solid Tumors
Interventions: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
Interventions: KPT-330; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Months to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Advanced Cancers
Interventions: MABp1; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: FOLFIRI regimen, bevacizumab, cetuximab, dulanermin, irinotecan; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • Redlands, California • San Francisco, California + 7 more

Conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions: PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Interventions: Sonrotoclax, Zanubrutinib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 17
States / cities: Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more

Conditions: Avascular Necrosis, Humeral Fractures
Interventions: Dual Energy Computed Tomography; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Colorectal Cancer, Appendix Cancer, Peritoneal Carcinomatosis
Interventions: Oxaliplatin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Open-angle Glaucoma
Interventions: PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham; Drug
Lead sponsor: Perfuse Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Renal Cell Carcinoma, Urinary Bladder Neoplasms
Interventions: Pembrolizumab, Vorinostat; Drug
Lead sponsor: Nabil Adra; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland

Search by objective public record fields.

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Acceptance and Commitment Therapy vs. Supportive Psychotherapy With Cystic Fibrosis Patients

A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

Thirty Million Words-Early Childhood Educator (TMW-ECE)

Perioperative Photobiomodulation in Facial Plastic Surgery

Gene Therapy Clinical Study in Adult PKU

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Early Parkinson's Disease (PD) Cross-Sectional

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Gene Therapy Study for Children With CLN5 Batten Disease

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

A First in Man Study of MABp1 in Patients With Advanced Cancers

A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

Study in Healthy Adults Evaluating PF-07202954

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

CT Imaging Evaluation of Humerus Fractures

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

A Study of PER-001 in Participants With Open-Angle Glaucoma

Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma